EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes

Darya Khvorost, Brittany Kendall, Ali R Jazirehi

Cells · 2024

DOI: 10.3390/cells13080662 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Darya Khvorost und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL) are hematological malignancies with high incidence rates that respond relatively well to conventional therapies. However, a major issue is the clinical emergence of patients with relapsed or refractory (r/r) NHL or ALL. In such circumstances, opportunities for complete remission significantly decline and mortality rates increase. The recent FDA approval of multiple cell-based therapies, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (Brexucabtagene autoleucel KTE-X19), and Breyanzi (Lisocabtagene Maraleucel), has provided hope for those with r/r NHL and ALL. These new cell-based immunotherapies use genetically engineered chimeric antigen receptor (CAR) T-cells, whose success can be attributed to CAR’s high specificity in recognizing B-cell-specific CD19 surface markers present on various B-cell malignancies and the subsequent initiation of anti-tumor activity. The efficacy of these treatments has led to promising results in many clinical trials, but relapses and adverse reactions such as cytokine release syndrome (CRS) and neurotoxicity (NT) remain pervasive, leaving areas for improvement in current and subsequent trials. In this review, we highlight the current information on traditional treatments of NHL and ALL, the design and manufacturing of various generations of CAR T-cells, the FDA approval of Kymriah, Yescarta Tecartus, and Breyanzi, and a summary of prominent clinical trials and the notable disadvantages of treatments. We further discuss approaches to potentially enhance CAR T-cell therapy for these malignancies, such as the inclusion of a suicide gene and use of FDA-approved drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsImmunotherapy, AdoptiveT-LymphocytesHumansAntigens, CD19B-LymphocytesImmunotherapyReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Stichwörter der Autor:innen

Acute Lymphoblastic Leukemiaapoptosiscelecoxibchromatin remodelingimmunotherapynon-Hodgkin’s lymphomasignal transduction

Substanzen

Antigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Life Sciences, Los Angeles City College (LACC), 855 N. Vermont Ave., Los Angeles, CA 90029, USA.
  • Department of Biological Sciences, College of Natural and Social Sciences, California State University, Los Angeles (CSULA), Los Angeles, CA 90032, USA.

Zitieren

APA

Khvorost, D., Kendall, B., & Jazirehi, A. R. (2024). Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes. Cells. https://doi.org/10.3390/cells13080662

Vancouver

Khvorost D, Kendall B, Jazirehi AR. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes. Cells. 2024. doi:10.3390/cells13080662

BibTeX
@article{Khvorost2024,
  author = {Khvorost, Darya and Kendall, Brittany and Jazirehi, Ali R},
  title = {Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13080662}
}
Kostenlos starten →